Post Reply
1-20 of 112
See https://www.investingnote.com/stocks/SGX:AP4#/all , Q1 2020 results is expected to be released today, after market close. Refer to the post by Kenny, he has checked in with Riverstone' s investment team.
DYOD
DYOD
High will go much higher as AEM.
the 1st quarter result will be out this month. anyone know when/?
AEM like. Staying vested.
Current price almost reflect its value. Wait for next push w news
newb1234 ( Date: 11-May-2020 09:51) Posted:
|
Riverstone also sells masks for 2 purposes... medical and semiconductor - 2 booming industry these days. dyodd.
I believe Riverstone also make and sell 2 tons of masks.
Longtermer ( Date: 11-May-2020 09:39) Posted:
|
Riverstone and UG manufacture Gloves.
Medtecs does PPE and provides medical services.
Demands are very high for their different products and services and benefited from crisis.
JY0064 ( Date: 08-May-2020 14:11) Posted:
|
:)
SmallSmall ( Date: 08-May-2020 11:02) Posted:
|
Very strong. Fresh buyers keep appearing w every selling
Anyone care to research Riverstone' s glove/PPE production capacity compared to Medtecs ?
Day high
SmallSmall ( Date: 08-May-2020 09:04) Posted:
|
All glove manufacturers in Malaysia have mostly automated their processes.
They are all basically churning out gloves ( money LOL ) asap ever since with Malaysia gov released their MCO.
Also with much higher salesprice, the coming profits will be unprecedented imo. Huat.
Sgvale ( Date: 08-May-2020 10:17) Posted:
|
W full automation, labour cost is reduced. W great market demand , just imagine the boss laughing to the bank.
Sgvale ( Date: 08-May-2020 10:17) Posted:
|
Riverstone boss said earlier his factories are fully automated before the Covid 19. Now all his machineries are running as fast as could meet the market demand.
Fresh from the oven
INITIATE COVERAGE
Riverstone Holdings (RSTON SP)
BUY | Price/Tgt: S$1.21/S$1.46 | Mkt Cap: S$896.7m
Beneficiary Of Industry Tailwinds From COVID-19
A leading global supplier of high-tech nitrile cleanroom gloves, Riverstone
has a dominant share of the hard disk drive market. It also manufactures
customised nitrile healthcare gloves. With consistent capacity expansion,
Riverstone is set to benefit from favourable industry tailwinds from the
COVID-19 pandemic and growing middle-income affluence. Given its attractive
48% discount to its peers&rsquo FY20 PE, we initiate coverage with BUY and a
PE-based target price of S$1.46.
· Global leader in nitrile cleanroom glove market. Riverstone Holdings
(Riverstone) specialises in the production of nitrile cleanroom gloves,
capturing a 60% global share of the hard disk drive market. As the
production of cleanroom gloves requires high levels of technical
capabilities, Riverstone&rsquo s customised nitrile cleanroom gloves command
ASPs that are 2.5-3.0x higher than that of nitrile healthcare gloves.
Riverstone&rsquo s cleanroom segment has been growing at double digits annually.
With the company&rsquo s proven track record, we believe this trend will
continue with Riverstone securing more orders.
· Capacity expansion to drive revenue and profits. Riverstone has a
newly-completed glove factory under phase 6 of its expansion plans,
boosting production capacity to 10.4b pieces/year by 1H20. Current
utilisation rates stand at 90-95%. Management has purchased land for phase
7-9 of its expansion plans. Phase 7 and 8 are expected to commence in 2020
and 2021 respectively, adding 1.4b pieces/year each and increasing total
capacity by 46.7% by 2022. In view of the higher capacity and favourable
tailwinds, we reckon the commissioning of these new production lines would
help boost Riverstone&rsquo s earnings.
· Changing demographic and macroeconomic trends to lift nitrile
healthcare gloves demand. Besides the ongoing COVID-19 pandemic, ageing
populations, rising middle-income affluence and greater health awareness
have contributed strongly to an increase in demand for healthcare gloves.
Developing countries such as China and India have low glove usage per
capita, implying huge potential in these countries. As Southeast Asia
contributes almost a third of Riverstone&rsquo s revenue, the company stands to
benefit from the rising living standards in these highly-populated
developing countries.
· Initiate coverage with BUY and PE-based target price of S$1.46,
pegged at 22x 2020F PE, a 38% discount to the sector&rsquo s 35.2x 2020F PE. The
discount is based on Riverstone&rsquo s 5-year average historical PE discount vs
the top 3 glovemakers&rsquo . The stock is currently trading at 18.2x 2020F PE.
We think this is unjustified as Riverstone has higher EBITDA margins, ROE
and dividend yield than peers, and comparable to that of industry leader
Hartalega.
Click on the link for details.
https://research.uobkayhian.com/content_download.jsp?id=56559& h=65bfcef588bc2037bf4cbc685e7138c0
INITIATE COVERAGE
Riverstone Holdings (RSTON SP)
BUY | Price/Tgt: S$1.21/S$1.46 | Mkt Cap: S$896.7m
Beneficiary Of Industry Tailwinds From COVID-19
A leading global supplier of high-tech nitrile cleanroom gloves, Riverstone
has a dominant share of the hard disk drive market. It also manufactures
customised nitrile healthcare gloves. With consistent capacity expansion,
Riverstone is set to benefit from favourable industry tailwinds from the
COVID-19 pandemic and growing middle-income affluence. Given its attractive
48% discount to its peers&rsquo FY20 PE, we initiate coverage with BUY and a
PE-based target price of S$1.46.
· Global leader in nitrile cleanroom glove market. Riverstone Holdings
(Riverstone) specialises in the production of nitrile cleanroom gloves,
capturing a 60% global share of the hard disk drive market. As the
production of cleanroom gloves requires high levels of technical
capabilities, Riverstone&rsquo s customised nitrile cleanroom gloves command
ASPs that are 2.5-3.0x higher than that of nitrile healthcare gloves.
Riverstone&rsquo s cleanroom segment has been growing at double digits annually.
With the company&rsquo s proven track record, we believe this trend will
continue with Riverstone securing more orders.
· Capacity expansion to drive revenue and profits. Riverstone has a
newly-completed glove factory under phase 6 of its expansion plans,
boosting production capacity to 10.4b pieces/year by 1H20. Current
utilisation rates stand at 90-95%. Management has purchased land for phase
7-9 of its expansion plans. Phase 7 and 8 are expected to commence in 2020
and 2021 respectively, adding 1.4b pieces/year each and increasing total
capacity by 46.7% by 2022. In view of the higher capacity and favourable
tailwinds, we reckon the commissioning of these new production lines would
help boost Riverstone&rsquo s earnings.
· Changing demographic and macroeconomic trends to lift nitrile
healthcare gloves demand. Besides the ongoing COVID-19 pandemic, ageing
populations, rising middle-income affluence and greater health awareness
have contributed strongly to an increase in demand for healthcare gloves.
Developing countries such as China and India have low glove usage per
capita, implying huge potential in these countries. As Southeast Asia
contributes almost a third of Riverstone&rsquo s revenue, the company stands to
benefit from the rising living standards in these highly-populated
developing countries.
· Initiate coverage with BUY and PE-based target price of S$1.46,
pegged at 22x 2020F PE, a 38% discount to the sector&rsquo s 35.2x 2020F PE. The
discount is based on Riverstone&rsquo s 5-year average historical PE discount vs
the top 3 glovemakers&rsquo . The stock is currently trading at 18.2x 2020F PE.
We think this is unjustified as Riverstone has higher EBITDA margins, ROE
and dividend yield than peers, and comparable to that of industry leader
Hartalega.
Click on the link for details.
https://research.uobkayhian.com/content_download.jsp?id=56559& h=65bfcef588bc2037bf4cbc685e7138c0
This counter more loyal supporter compared to UG there full with traders
troylee ( Date: 21-Apr-2020 15:13) Posted:
|
Stirring......
Sgvale ( Date: 30-Apr-2020 14:06) Posted:
|
Target $1.30. Then $1.50
Yay, hope so...
Sgvale ( Date: 22-Apr-2020 16:07) Posted:
|